DrugPatentWatch Database Preview

Details for Patent: 7,678,770

« Back to Dashboard

Which drugs does patent 7,678,770 protect, and when does it expire?

Patent 7,678,770 protects VYVANSE and is included in two NDAs.

This patent has one hundred and forty-three patent family members in twenty-six countries.

Summary for Patent: 7,678,770

Title:	Abuse-resistant amphetamine prodrugs
Abstract:	The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s):	Mickle; Travis (Coralville, IA), Krishnan; Suma (Belvedere, CA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Oberlender; Robert (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Paul; Bernhard J. (Lexington, MA), Verbicky; Christopher A. (Broadalbin, NY)
Assignee:	Shire LLC (Florence, KY)
Application Number:	12/201,739
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,678,770
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 7,678,770

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Shire Development	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-007	Oct 30, 2014		RX	Yes	No						INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-004	Dec 10, 2007		RX	Yes	No						INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-001	Feb 23, 2007		RX	Yes	No						INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977-005	Dec 10, 2007		RX	Yes	No						INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Non-Orange Book US Patents Family Members for Patent 7,678,770

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,687,467	Abuse-resistant amphetamine prodrugs
7,223,735	Abuse resistant lysine amphetamine compounds
7,060,708	Active agent delivery systems and methods for protecting and administering active agents
8,343,927	Pharmaceutical compositions for prevention of overdose or abuse

International Family Members for US Patent 7,678,770

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	462411
Austria	462412
Austria	519502
Austria	533512